Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06418594
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-17
First Post:
2024-05-13
Brief Title:
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Sponsor:
Beijing 302 Hospital
Organization:
Beijing 302 Hospital
Organization Data
Organization:
Beijing 302 Hospital
Class:
OTHER
Study ID:
MA-BC-II-070
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Beijing 302 Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Wang Tao
Responsible Party Title:
Professor
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Beijing 302 Hospital
Old Name:
None
Old Organization:
None